£500k funding boost for regenerative medicine firm

12 February 2018

A regenerative medicine company which has developed a therapy that can help prevent sight loss has completed a £500,000 funding round backed by Mercia Fund Managers, angel investors and the University of Nottingham.

The investment will allow Nottingham-based NuVision Biotherapies to further develop its product range, add to its management team and increase sales in the UK and internationally.

NuVision was set up in 2015 with funding from Mercia to commercialise research work carried out at the university by Andy Hopkinson, who is now the company’s chief executive.

Its wound-healing therapy uses the regenerative properties of amniotic tissue, which is found in the sac surrounding babies in the womb and is normally discarded at birth.

Read the full article here.